Table 2: Comparison of Medication in Different Trials.

	Troughton et al.	STARS-BNP	TIME-CHF	PRIMA	Berger et al.	BATTLE-SCARRED	Anguita et al.	SIGNAL-HF	UPSTEP	PROTECT	STAR-BRITE
ACE/ARB	100 %	99 %	95 %	79 %	89 %	82 %	93 %	~90 %	74 %	81 %	88 %
β-Blocker	8 %	98 %	79%	77 %	77 %	68 %	60 %	97 %	94 %	96 %	83 %
Diuretics	100 %	100 %	93 %	96 %	81 %	95 %	93 %	68 %	90 %	91 %	93 %
ACE/ARB ↑	Yes	Yes	Yes	(Yes)	Yes	Yes	No	(Yes)	Yes*	Yes	No
β-Blocker ↑	No	Yes	Yes	No	Yes	Yes	No	No	No	Yes	Yes
Spironolac. ↑	Yes	Yes	Yes	No	No	No	No	No	No	Yes	No
Diuretics ↑	No	No	No	Yes	Decrease	Yes	No	No	No	Decrease	No
More AEs	No	No	No	No	?	No	?	No	No	Trend	No

First three rows indicate baseline therapy and following rows adjustment during the course of the studies. *indicates ARB only; ↑ = significant increase during trial in natriuretic peptide-guided group as compared with control group; medication in % indicates baseline use of these drugs, not considering dose. ACE = angiotensin-converting enzyme; AE = adverse event; ARB = angiotensin II receptor blocker.